IE00BF0H7608
IE00BF0H7608
L&G Pharma Breakthrough UCITS ETF
Loading chart...
About this ETF
The L&G Pharma Breakthrough UCITS ETF seeks to track the Solactive Pharma Breakthrough Value index. The Solactive Pharma Breakthrough Value index tracks companies involved in the development and manufacturing of so-called "orphan drugs". Orphan drugs are drugs that target very rare diseases.
TER
0.49%
Total Expense Ratio per year
Fund Size
€19.28M
Assets under management
Holdings
41
Underlying equities
Dividend Yield
0%
Accumulating
Fundamentals & Estimates
Weighted valuation multiples and analyst forecasts
Valuation Multiples
Weighted P/E
16.84
Weighted Fwd P/E
20.34
💰 Revenue Estimates
Current Year CY
+23.63% ⌀ 14 Analysts Coverage
Next Year NY
+13.72% ⌀ 14 Analysts Coverage
📈 EPS Estimates (Earnings Per Share)
Current Year CY
-40.13% ⌀ 11 Analysts Coverage
Next Year NY
+237.06% ⌀ 11 Analysts Coverage
Related ETFs
Xtrackers World Small Cap Green Tech Innovators UCITS ETF 1C
39.04 EUR
TER 0.45% 1Y +24.6%
Xtrackers World Green Tech Innovators UCITS ETF 1C
35.22 EUR
TER 0.35% 1Y +16.6%
Xtrackers MSCI Genomic Healthcare Innovation UCITS ETF 1C
42.35 USD
TER 0.3% 1Y +68.6%
ETF Profile
Provider
Fund Type
ETF Type
Passive Inception Date
01/23/2018 (8 yrs)
Index Group
Solactive Pharma Breakthrough Value Region
World Country
-
Sector
Health Care Strategy
-
Theme
Innovation Distribution Policy
Accumulating Replication
Full replication Sustainable
No 🛡️ Risk & Structural Analysis
Multi-Factor Risk Model & Market Data
5/7 Elevated
Diversification Score: 17/100 Low (Concentration Risk)
Diversification Score
17/100 Low (Concentration Risk)
5Y Volatility
18.8% p.a.
Max Drawdown (5Y)
-33.6%
Sharpe Ratio (5Y)
-0.01
Beta Factor
0.65
Notes & Warnings
Fund Volume (AUM) ⚠️ Fund closure risk (< 50M € AUM)
⚠️ Fund closure risk (< 50M € AUM)
🟡 Moderate analyst coverage (10.8 analysts)
🔴 Severe sector concentration risk: 98% in "Healthcare".
🔴 Extreme industry concentration: 63% in "Biotechnology".
⚠️ Elevated Regulatory & Policy Risk: 98% in heavily regulated industries (defense, regulated utilities, healthcare policy).